<DOC>
	<DOC>NCT02280590</DOC>
	<brief_summary>Comparison of the efficacy and safety of Cresnon® and Crestor® in patients with hyperlipidemia - 8-week, active-controlled, open-label, randomized, parallelgroup, fixed-dose, noninferiority, multicenter, phase 4 design</brief_summary>
	<brief_title>Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Age ≥ 20 Persons who have not reached LDLC targeted level in accordance with the treatment guidelines for dyslipidemia released by Korean Society of Lipidology and Atherosclerosis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>